Taking a Toll on Self-Renewal: TLR-Mediated Innate Immune Signaling in Stem Cells

Trends in Neurosciences

Volumn 39, Issue 7, 2016, Pages 463-471

  Alvarado, Alvaro G ^a,b   Lathia, Justin D ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

cancer stem cells; glioblastoma; neural progenitor cells; Toll like receptor

Indexed keywords

TOLL LIKE RECEPTOR;

BRAIN CANCER; BRAIN DEVELOPMENT; CANCER STEM CELL; CELL INFILTRATION; CELL SELF-RENEWAL; DEVELOPMENT; DISEASES; GLIOBLASTOMA; GLIOMA; HOMEOSTASIS; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; MICROENVIRONMENT; NERVE CELL; NERVE DEGENERATION; NERVE INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; ANIMAL; BRAIN; BRAIN TUMOR; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANIMALS; BRAIN; BRAIN NEOPLASMS; HUMANS; IMMUNITY, INNATE; STEM CELLS; TOLL-LIKE RECEPTORS;

EID: 84964895950     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2016.04.005     Document Type: Review

References (88)

1. 1 Hashimoto, C., et al. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 52 (1988), 269–279.
2. 2 Lemaitre, B., et al. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86 (1996), 973–983.
3. 3 Medzhitov, R., et al. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 (1997), 394–397.
4. 4 Takeda, K., Akira, S., Toll-like receptors. Curr. protoc. Immuno. 109 (2015), 14.12.1–14.12.10.
5. 5 van Noort, J.M., Bsibsi, M., Toll-like receptors in the CNS: implications for neurodegeneration and repair. Prog. Brain. Res. 175 (2009), 139–148.
6. 6 Okun, E., et al. Toll-like receptors in neurodegeneration. Brain. Res. Rev. 59 (2009), 278–292.
7. 7 Jack, C.S., et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. J. Immunol. 175 (2005), 4320–4330.
8. + stromal cells. J. Immunol. 193 (2014), 2218–2229.
9. 9 Xu, J., et al. TLR4 deters perfusion recovery and upregulates TLR2 in ischemic skeletal muscle and endothelial cells. Mol. Med. 21 (2015), 605–615.
10. 10 Aflatoonian, R., Fazeli, A., Toll-like receptors in female reproductive tract and their menstrual cycle dependent expression. J. Reprod. Immunol. 77 (2008), 7–13.
11. 11 Hu, J., et al. Activation of Toll like receptor 3 induces spermatogonial stem cell apoptosis. Cell Biochem. Funct. 33 (2015), 415–422.
12. 12 Niedzielska, I., et al. Toll-like receptors and the tendency of normal mucous membrane to transform to polyp or colorectal cancer. J. Physio. Pharmacol. 60:Suppl. 1 (2009), 65–71.
13. 13 Fusaru, A.M., et al. Role of innate immune receptors TLR2 and TLR4 as mediators of the inflammatory reaction in human visceral adipose tissue. Rom. J. Morphol. Embryol. 53 (2012), 693–701.
14. 14 Nativel, B., et al. Soluble HMGB1 is a novel adipokine stimulating IL-6 secretion through RAGE receptor in SW872 preadipocyte cell line: contribution to chronic inflammation in fat tissue. PloS ONE, 8, 2013, e76039.
15. 15 Gluba, A., et al. The role of Toll-like receptors in renal diseases. Nat. Rev. Nephrol. 6 (2010), 224–235.
16. 16 Liu, L., et al. Small interfering RNA targeting Toll-like receptor 9 protects mice against polymicrobial septic acute kidney injury. Nephron Exp. Nephrol. 122 (2012), 51–61.
17. 17 Saito, T., et al. Toll-like receptor mRNA expression in liver tissue from patients with biliary atresia. J. Pediatr. Gastroenterol. Nutr. 53 (2011), 620–626.
18. 18 Yang, L.S., et al. Role of toll-like receptors in lung cancer. J. Recept. Signal Transduct. Res. 34 (2014), 342–344.
19. 19 Nishimura, M., Naito, S., Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol. Pharm. Bull. 28 (2005), 886–892.
20. 20 Piccinini, A.M., Midwood, K.S., DAMPening inflammation by modulating TLR signalling. Mediators. Inflamm., 2010, 2010, 672395.
21. 21 Taniguchi, N., et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 48 (2003), 971–981.
22. 22 Andersson, A., et al. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J. Leukoc. Biol. 84 (2008), 1248–1255.
23. 23 Orend, G., Chiquet-Ehrismann, R., Tenascin-C induced signaling in cancer. Cancer Lett. 244 (2006), 143–163.
24. 24 Rybarczyk, B.J., Simpson-Haidaris, P.J., Fibrinogen assembly, secretion, and deposition into extracellular matrix by MCF-7 human breast carcinoma cells. Cancer Res. 60 (2000), 2033–2039.
25. 25 Trotta, T., et al. Biological role of Toll-like receptor-4 in the brain. J. Neuroimmunol. 268 (2014), 1–12.
26. 26 Shemer, A., et al. Microglia plasticity during health and disease: an immunological perspective. Trends Immunol. 36 (2015), 614–624.
27. 27 Okun, E., et al. Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci. 34 (2011), 269–281.
28. 28 Hemmi, H., Akira, S., TLR signalling and the function of dendritic cells. Chem. Immunol. Allergy 86 (2005), 120–135.
29. 29 Gorina, R., et al. Astrocyte TLR4 activation induces a proinflammatory environment through the interplay between MyD88-dependent NFkappaB signaling, MAPK, and Jak1/Stat1 pathways. Glia 59 (2011), 242–255.
30. 30 Jung, D.Y., et al. TLR4, but not TLR2, signals autoregulatory apoptosis of cultured microglia: a critical role of IFN-beta as a decision maker. J. Immunol. 174 (2005), 6467–6476.
31. 31 Lathia, J.D., et al. Toll-like receptor 3 is a negative regulator of embryonic neural progenitor cell proliferation. J. Neurosci. 28 (2008), 13978–13984.
32. 32 Okun, E., et al. TLR2 activation inhibits embryonic neural progenitor cell proliferation. J. Neurochem. 114 (2010), 462–474.
33. 33 Rolls, A., et al. Toll-like receptors modulate adult hippocampal neurogenesis. Nat. Cell Biol. 9 (2007), 1081–1088.
34. 34 Bsibsi, M., et al. Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. Glia 53 (2006), 688–695.
35. 35 Sloane, J.A., et al. Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 11555–11560.
36. 36 Ma, Y., et al. TLR8: an innate immune receptor in brain, neurons and axons. Cell Cycle 6 (2007), 2859–2868.
37. 37 Ma, Y., et al. Toll-like receptor 8 functions as a negative regulator of neurite outgrowth and inducer of neuronal apoptosis. J. Cell Biol. 175 (2006), 209–215.
38. 38 Covacu, R., et al. TLR activation induces TNF-alpha production from adult neural stem/progenitor cells. J. Immunol. 182 (2009), 6889–6895.
39. 39 Wu, H.M., et al. Microglial activation mediates host neuronal survival induced by neural stem cells. J. Cell. Mol. Med. 18 (2014), 1300–1312.
40. 40 Bhatelia, K., et al. TLRs: linking inflammation and breast cancer. Cell. Signal. 26 (2014), 2350–2357.
41. 41 Yusuf, N., Toll-like receptor mediated regulation of breast cancer: a case of mixed blessings. Front. Immunol., 5, 2014, 224.
42. + cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression. Eur. J. Cancer 46 (2010), 2849–2857.
43. 43 Li, T.T., et al. Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy. World J. Gastroenterol. 20 (2014), 17699–17708.
44. 44 Lu, C.C., et al. Upregulation of TLRs and IL-6 as a marker in human colorectal cancer. Int. J. Mol. Sci. 16 (2015), 159–177.
45. 45 Santoni, M., et al. Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target. Cancer Treat. Rev. 41 (2015), 569–576.
46. 46 Vaz, J., Andersson, R., Intervention on toll-like receptors in pancreatic cancer. World J. Gastroenterol. 20 (2014), 5808–5817.
47. 47 Galli, R., et al. TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types. J. Immunol. 184 (2010), 6658–6669.
48. 48 Zhao, S., et al. Toll-like receptors and prostate cancer. Front. Immunol., 5, 2014, 352.
49. 49 Huang, Y., et al. Gene silencing of Toll-like receptor 2 inhibits proliferation of human liver cancer cells and secretion of inflammatory cytokines. PloS One, 7, 2012, e38890.
50. 50 Chatterjee, S., et al. TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. Cancer Res. 74 (2014), 5008–5018.
51. 51 Ke, X., et al. Activation of Toll-like receptors signaling in non-small cell lung cancer cell line induced by tumor-associated macrophages. Chin. J. Cancer Res. 27 (2015), 181–189.
52. 4 instructs commitment of human hematopoietic stem cells to a myeloid cell fate. Leukemia 23 (2009), 2063–2074.
53. 53 Ignatz-Hoover, J.J., et al. The role of TLR8 signaling in acute myeloid leukemia differentiation. Leukemia 29 (2015), 918–926.
54. 54 Morrison, C., et al. Effects of Toll-like receptor signals in T-cell neoplasms. Future Oncol. 7 (2011), 309–320.
55. 55 Husseinzadeh, N., Davenport, S.M., Role of toll-like receptors in cervical, endometrial and ovarian cancers: a review. Gynecol. Oncol. 135 (2014), 359–363.
56. 56 Szajnik, M., et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 28 (2009), 4353–4363.
57. 57 Galli, R., et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64 (2004), 7011–7021.
58. 58 Ignatova, T.N., et al. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39 (2002), 193–206.
59. 59 Singh, S.K., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63 (2003), 5821–5828.
60. 60 Singh, S.K., et al. Identification of human brain tumour initiating cells. Nature 432 (2004), 396–401.
61. 61 Chen, J., et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488 (2012), 522–526.
62. 62 Bao, S., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (2006), 756–760.
63. 63 Dragu, D.L., et al. Therapies targeting cancer stem cells: current trends and future challenges. World J. Stem Cells 7 (2015), 1185–1201.
64. 64 Lathia, J.D., et al. Cancer stem cells in glioblastoma. Genes Dev. 29 (2015), 1203–1217.
65. 65 Alexander, B.M., et al. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 17 (2015), 180–188.
66. 66 Prados, M.D., et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 17 (2015), 1051–1063.
67. 67 Larkin, J., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373 (2015), 23–34.
68. 68 Reardon, D.A., et al. Immunotherapy advances for glioblastoma. Neuro Oncol. 16 (2014), 1441–1458.
69. 69 Deng, S., et al. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma. Protein Cell 5 (2014), 899–911.
70. 70 Herrmann, A., et al. TLR9 is critical for glioma stem cell maintenance and targeting. Cancer Res. 74 (2014), 5218–5228.
71. 71 Leng, L., et al. TLR9 expression is associated with prognosis in patients with glioblastoma multiforme. J. Clin. Neurosci. 19 (2012), 75–80.
72. 72 Meng, Y., et al. Expression of TLR9 within human glioblastoma. J. Neurooncol. 88 (2008), 19–25.
73. 73 Guryanova, O.A., et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 19 (2011), 498–511.
74. 74 Kim, E., et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23 (2013), 839–852.
75. 75 Sherry, M.M., et al. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 27 (2009), 2383–2392.
76. 76 Gupta, P., et al. Beta-defensin-3 negatively regulates TLR4–HMGB1 axis mediated HLA-G expression in IL-1beta treated glioma cells. Cell. Signal. 25 (2013), 682–689.
77. 77 Sarrazy, V., et al. TLR4 signal transduction pathways neutralize the effect of Fas signals on glioblastoma cell proliferation and migration. Cancer Lett. 311 (2011), 195–202.
78. 78 Tewari, R., et al. Involvement of TNFalpha-induced TLR4–NF-kappaB and TLR4–HIF-1alpha feed-forward loops in the regulation of inflammatory responses in glioma. J. Mol. Med. 90 (2012), 67–80.
79. 79 Heddleston, J.M., et al. Hypoxia inducible factors in cancer stem cells. Br. J. Cancer 102 (2010), 789–795.
80. 80 Soeda, A., et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28 (2009), 3949–3959.
81. 81 Vinnakota, K., et al. Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion. Neuro Oncol. 15 (2013), 1457–1468.
82. 82 Hu, F., et al. Glioma-associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline. Int. J. Cancer 135 (2014), 2569–2578.
83. 83 Markovic, D.S., et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 12530–12535.
84. 84 Akira, S., Hemmi, H., Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 85 (2003), 85–95.
85. 85 Tang, D., et al. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol. Rev. 249 (2012), 158–175.
86. 86 Kawai, T., Akira, S., TLR signaling. Semin. Immunol. 19 (2007), 24–32.
87. 87 Feldman, N., et al. DAMPs as mediators of sterile inflammation in aging-related pathologies. Ageing Res. Rev. 24 (2015), 29–39.
88. 88 Rock, K.L., et al. The sterile inflammatory response. Annu. Rev. Immunol. 28 (2010), 321–342.